Although our results provide reassurance that APOE ε4 status does not appear to play a significant role in dramatic cognitive changes in breast cancer survivors, late effects and interaction with endocrine therapy remain an important area of future hypothesis-driven research in both cognitively intact and cognitively vulnerable samples. This evidence concerns the gene APOE and breast carcinoma.